Eli Lilly | LLY
Stock Price
747.50
Daily Change
-0.71 -0.09%
Monthly
-17.11%
Yearly
24.36%
Q4 Forecast
797.92


Peers Price Chg Day Year Date
AbbVie 177.16 5.32 3.10% 27.76% Nov/22
Abbott 117.76 0.42 0.36% 14.47% Nov/22
ALKERMES 28.78 1.08 3.90% 18.00% Nov/22
Amgen 294.64 4.72 1.63% 10.99% Nov/22
AstraZeneca 10,474.00 412.00 4.09% 2.95% Nov/22
Baxter International 33.22 0.23 0.68% -7.77% Nov/22
Biogen 157.88 -0.16 -0.10% -31.93% Nov/22
Bristol-Myers Squibb 58.86 0.66 1.13% 18.29% Nov/22
Catalent 60.91 1.27 2.12% 52.30% Nov/22
Gilead Sciences 90.01 0.40 0.45% 19.41% Nov/22
GlaxoSmithKline 1,342.00 32.50 2.48% -5.56% Nov/22
Glaxosmithkline 33.96 0.26 0.77% -5.17% Nov/22
J&J 155.20 -0.32 -0.21% 1.77% Nov/22
Eli Lilly 747.50 -0.71 -0.09% 24.36% Nov/22
Medtronic 86.39 1.62 1.92% 9.40% Nov/22
Merck 99.27 -0.86 -0.86% -2.55% Nov/22
Neurocrine Biosciences 125.65 0.65 0.52% 12.02% Nov/22
Novartis 93.68 2.12 2.32% 8.61% Nov/22
Novartis 104.31 0.54 0.52% 6.28% Nov/22
Prestige Brands 84.85 0.71 0.84% 45.49% Nov/22
Pfizer 25.66 0.56 2.23% -15.87% Nov/22
Perrigo 28.07 1.01 3.73% -9.09% Nov/22
Drreddys Laboratories 14.20 0.21 1.50% -79.19% Nov/22
Regeneron Pharmaceuticals 738.00 -5.43 -0.73% -7.55% Nov/22
Roche Holding 254.30 3.20 1.27% 6.69% Nov/22
Sanofi 93.17 2.30 2.53% 8.04% Nov/22
Sanofi 48.25 0.27 0.55% 2.26% Nov/22
United Therapeutics 372.89 5.53 1.51% 61.33% Nov/22
Zoetis 177.15 0.46 0.26% -1.70% Nov/22

Indexes Price Day Year Date
US500 5969 20.64 0.35% 30.93% Nov/22

Eli Lilly traded at $747.50 this Friday November 22nd, decreasing $0.71 or 0.09 percent since the previous trading session. Looking back, over the last four weeks, Eli Lilly lost 17.11 percent. Over the last 12 months, its price rose by 24.36 percent. Looking ahead, we forecast Eli Lilly to be priced at 797.92 by the end of this quarter and at 768.84 in one year, according to Trading Economics global macro models projections and analysts expectations.

Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.